In the last 2 years, the US Food and Drug Administration granted accelerated approval or approval to specific fusion gene drugs in non-small-cell lung cancer (NSCLC) for REarranged during Transfection proto-oncogene gene/RET (selpercatinib), ROS proto-oncogene 1/ROS1 (alectinib or entrectinib), anaplastic lymphoma receptor tyrosine kinase/ALK (crizotinib, alectinib, etc.), and neurotrophic tyrosine receptor kinase/NTRK (entrectinib) fusions. Here, RET is linked to non-small cell lung carcinoma.